Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Topol

Cardiovascular Disease La Jolla, CA Medical Doctor

NPI 1487723714 CMS profile 203831

10666 N Torrey Pines Rd, La Jolla, CA 92037

Open in the dashboard

General payments

$2,226,784

42 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$20,991 paid to institutions, not to them · program years 2020–2023

Through program year 2025, Eric Topol of La Jolla, CA is reported in the CMS Open Payments database as having received $2,226,784 across 42 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $20,991 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51,335 7
2024 General $349,199 10
2023 General $492,714 7
2022 General $343,323 9
2021 General $314,806 3
2020 General $338,055 2
2019 General $337,353 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Topol
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Eric Topol were reported at $51,335. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Eric Topol Cardiovascular Disease median Middle half National median
2019 $337,353 $450 $127–$1,392 $163
2020 $338,055 $242 $77–$751 $114
2021 $314,806 $335 $101–$1,037 $132
2022 $343,323 $395 $121–$1,211 $149
2023 $492,714 $443 $136–$1,283 $160
2024 $349,199 $450 $136–$1,323 $164
2025 $51,335 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dexcom, Inc. $2,120,710 22 payments
  2. Carlsmed, Inc. $50,896 3 payments
  3. Illumina, Inc. $48,075 9 payments
  4. Genentech USA, Inc. $5,598 3 payments
  5. Cue Health Inc. $867 1 payment
  6. Boston Scientific Corporation $400 1 payment
  7. Asahi Intecc USA, Inc. $213 2 payments
  8. Acist Medical Systems, Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $815,391 3 payments
  2. Current or prospective ownership or investment interest $651,954 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $433,393 7 payments
  4. Grant $317,371 1 payment
  5. Food and Beverage $3,932 19 payments
  6. Travel and Lodging $3,282 7 payments
  7. Gift $1,448 2 payments
  8. Entertainment $13 1 payment
Products named General payments · program years 2019–2025
  1. Dexcom G6 CGM System $338,055 2 payments
  2. DEXCOM CGM $337,353 4 payments
  3. Dexcom G6 Transmitter Endocrinology $317,371 1 payment
  4. DEXCOM G6 TRANSMITTER Endocrinology $314,381 1 payment
  5. aprevo $50,500 1 payment
  6. NovaSeq 6000Dx Sequencer Instrument Devices $23,990 2 payments
  7. Infectious Disease $22,990 2 payments
  8. NovaSeq 6000Dx Sequencer Instrument Genetics $1,095 5 payments
  9. Cue Health Monitoring System $867 1 payment
  10. General Therapies $400 1 payment
  11. Other $634 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$4,712

Medicare's payments for the services billed

Medicare patients

36

Average age 76

Services billed

43

12 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 42%
Atrial fibrillation 42%
Arthritis 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record